EP3684362A1 - Formulation de nicotine - Google Patents

Formulation de nicotine

Info

Publication number
EP3684362A1
EP3684362A1 EP19727687.6A EP19727687A EP3684362A1 EP 3684362 A1 EP3684362 A1 EP 3684362A1 EP 19727687 A EP19727687 A EP 19727687A EP 3684362 A1 EP3684362 A1 EP 3684362A1
Authority
EP
European Patent Office
Prior art keywords
acid
formulation
nicotine
oil
ester
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP19727687.6A
Other languages
German (de)
English (en)
Other versions
EP3684362B1 (fr
Inventor
Christopher NOLAN
Joseph KAVANAGH
Kieran RALEIGH
Brian O'rourke
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yatzz Ltd
Original Assignee
Yatzz Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yatzz Ltd filed Critical Yatzz Ltd
Priority to PL19727687T priority Critical patent/PL3684362T3/pl
Priority to EP21174043.6A priority patent/EP3909581A1/fr
Publication of EP3684362A1 publication Critical patent/EP3684362A1/fr
Application granted granted Critical
Publication of EP3684362B1 publication Critical patent/EP3684362B1/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/465—Nicotine; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
    • A24B—MANUFACTURE OR PREPARATION OF TOBACCO FOR SMOKING OR CHEWING; TOBACCO; SNUFF
    • A24B15/00—Chemical features or treatment of tobacco; Tobacco substitutes, e.g. in liquid form
    • A24B15/10—Chemical features of tobacco products or tobacco substitutes
    • A24B15/16—Chemical features of tobacco products or tobacco substitutes of tobacco substitutes
    • A24B15/167—Chemical features of tobacco products or tobacco substitutes of tobacco substitutes in liquid or vaporisable form, e.g. liquid compositions for electronic cigarettes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0085—Inhalators using ultrasonics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/06—Inhaling appliances shaped like cigars, cigarettes or pipes

Definitions

  • the present invention relates to a pharmaceutical formulation comprising nicotine and a high volume of water.
  • the formulation can be aerosolised at ambient temperature for delivery via inhalation.
  • the invention also relates to a method of delivering nicotine to a subject via inhalation, and specifically via the use of a nebuliser.
  • the formulation can be delivered via a conventional e-cigarette device.
  • Nicotine replacement therapies are pharmaceutical therapies which administer nicotine by means other than smoking tobacco, while allowing a user to mimic the effect of cigarette smoking. NRTs are associated with increased success at smoking cessation compared with placebos (Silagy et al. "Nicotine replacement therapy for smoking cessation", Cochrane Database of Systematic Reviews 2004;(3):CD000146). NRTs typically include transdermal patches, gums, oral and nasal sprays, inhalers, tablets and lozenges. However, NRTs suffer from a number of disadvantages, and primarily from inferior nicotine pharmacokinetic (PK) profiles when compared with combustible cigarettes (CCs).
  • PK nicotine pharmacokinetic
  • E-cigarettes are handheld devices, often made to look like conventional CCs, and can be used by smokers to mimic the smoking action.
  • E-cigarettes typically comprise a mouthpiece, a cartridge, an atomiser, a microprocessor, and a battery.
  • the cartridge contains an e-liquid, which comprises the nicotine in viscous solvents such as vegetable glycerine and propylene glycol.
  • the e-liquid is heated to high temperatures in the e-cigarette to form a vapour, which is inhaled by the user.
  • the global use of e-cigarettes has increased exponentially since their introduction into consumer markets in 2004, with estimated global sales of US$7 billion annually (World Health Organisation, Backgrounder on WHO report on regulation of e-cigarettes and similar products).
  • known e- cigarettes often do not provide a PK profile comparable to that of CCs, and as such do not reduce the urge to smoke for many users.
  • smoking of both conventional CCs and e-cigarettes involves heating of the nicotine formulation in order to combust or vaporise the ingredients for inhalation. This heating results in the generation of undesirable by-products which are known to have an adverse effect on health. While the majority of toxic chemicals found in tobacco smoke from conventional CCs are absent in e-cigarette vapour, e-cigarettes still generate toxicants and traces of heavy metals (Hajek et al. Addiction. 2014 November; 109(11): 1801-1810). In addition, e-cigarette vapour can be inhaled passively by third parties.
  • a pharmaceutical formulation comprising 0.1-8% wt. % of nicotine; at least 65 wt.% water; and one or more of flavouring agents, co-solubilisers and solubilisers; wherein the nicotine is the form of a nicotine salt of nicotine and an acid; and wherein the pharmaceutical formulation has an acidic pH.
  • the formulation may be an inhalable pharmaceutical formulation.
  • a method of delivering nicotine to a subject comprising providing an aerosolised formulation comprising 0.1-8% wt % of nicotine and at least 65 wt.% water; and administering the aerosolised formulation via inhalation.
  • the method may comprise providing the formulation as a liquid and nebulizing the liquid formulation to form an aerosolised formulation for inhalation.
  • Figure 1 shows venous blood plasma concentrations of nicotine pre- and post-inhalation of a formulation according to the invention.
  • the present invention relates to a pharmaceutical formulation
  • a pharmaceutical formulation comprising 0.1-8% wt % of nicotine; at least 65 wt.% water; and one or more of flavouring agents, co-solubilisers and solubilisers.
  • the nicotine is included in the formulation in the form of a salt of nicotine and an acid, or salts of nicotine and an acid.
  • the pharmaceutical formulation has an acidic pH.
  • the formulation comprises high volumes of water. This results in a decrease in the amount of deleterious side-products produced when the formulation is aerosolised, and subsequently inhaled by a subject.
  • the high volumes of water in the formulation lead to improved PK behaviour, with PK curves of the formulations according to the invention demonstrating correlation with those of CCs.
  • a high water content also facilitates aerosol production.
  • the formulation comprises at least 70 wt.% of water. In another embodiment, the formulation comprises at least 75 wt.% of water, or at least 80 wt.% of water.
  • Typical formulations for e-cigarettes comprise large volumes ( ⁇ > 60%) of viscous chemicals such as glycerine and propylene glycol. Heating to high temperatures is required to volatilize these components for administration, resulting in the generation of harmful by products. In the formulation of the present invention, however, low quantities of such viscous chemicals are used. Specifically, the formulation of the present invention does not comprise viscous chemicals such as glycerine and propylene glycol in large quantities. In an embodiment, the formulation comprises less than 20%, and preferably less than 15% in total of propylene glycol and glycerine.
  • HFCs hydrofluorocarbons
  • Other known formulations comprise ingredients such as hydrofluorocarbons (HFCs), which are used in respiratory drug delivery.
  • HFCs hydrofluorocarbons
  • the high volumes of water in the formulation according to the invention mitigate the need to heat the formulation to high temperatures for inhalation, resulting in a decrease in harmful by-products.
  • the formulation also avoids the use of HFCs, with their associated disadvantages.
  • the formulation of the invention does not comprise hydrofluorocarbons.
  • the nicotine is included in the formulation at a concentration of from 0.1 to 8 weight %.
  • the formulation can comprise varying amounts of nicotine to assist in smoking reduction or cessation in a user.
  • the nicotine is included in the formulation at a concentration of from 0.1 to 5% of nicotine, or from 0.1 to 3% of nicotine. Within this range, formulations comprising from 0.3-0.6%, from 1-1.2%, from 1.6-1.9% and from 2.1-2.5% may be preferred.
  • Nicotine (3-(l-methyl-2-pyrrolidinyl)-pyridine) may be naturally-occurring nicotine, or may be a synthetic nicotine.
  • the nicotine is included in the form of a salt.
  • the lower pH of the nicotine salt versus free base nicotine attenuates the irritating effect of the nicotine and results in a more palatable formulation.
  • a single salt or a mixture of nicotine salts may be used.
  • Suitable acids for forming the nicotine salt must exhibit minimal or no toxicity to humans.
  • the acid is selected from acetic acid, acetylsalicylic acid, alginic acid, 2- aminoethanesulfonic acid (taurine), aminomethylphosphonic acid, arachidic acid, ascorbic acid, aspartic acid, azelaic acid, barbituric acid, benzylic acid, benzoic acid, butanoic acid, butyric acid, capric acid, caproic acid, caprylic acid, carbonic acid, cinnamic acid, citric acid, decanoic acid, dodecanoic acid, enanthic acid, ethanoic acid, folic acid, formic acid, fumaric acid, gallic acid, gentisic acid, gluconic acid, glutamic acid, glutaric acid, heptanoic acid, hexanoic acid, hydrochloric acid, icosanoic acid, ketobutyric acid, lactic acid, lauric acid, levulinic acid, malic acid, male
  • the acid is selected from lactic acid, acetylsalicylic acid, 2- aminoethanesulfonic acid (taurine), aminomethylphosphonic acid, arachidic acid, ascorbic acid, azelaic acid, barbituric acid, benzylic acid, butanoic acid, capric acid, caproic acid, caprylic acid, carbonic acid, cinnamic acid, decanoic acid, dodecanoic acid, enanthic acid, ethanoic acid, folic acid, fumaric acid, gluconic acid, glutaric acid, heptanoic acid, hexanoic acid, icosanoic acid, ketobutyric acid, levulinic acid, maleic acid, malonic acid, margaric acid, methanoic acid, 2-methylpropanoic acid (isobutyric acid), 3,7-dimethyl-6-octenoic acid (citronellic acid), myristic acid, nonadecan
  • pentadecylic acid pentanoic acid, propanoic acid, propiolic acid, rosolic acid, sorbic acid, stearic acid and succinic acid, tetradecanoic acid, p-toluenesulfonic acid, tridecanoic acid, tridecylic acid, trifluoroacetic acid, trifluoromethanesulfonic acid, undecanoic acid, undecylic acid and uric acid.
  • the acid is lactic acid.
  • Lactic acid is a naturally-occurring organic acid and is native to the human body, making it suitable for use in the pharmaceutical formulation of the invention.
  • the acid is 2-methylpropanoic acid (isobutyric acid).
  • Isobutyric acid imparts a dairy/cheesy flavoured note to the formulation, thereby improving palatability and therefore isobutyric acid, along with butyric acid which has a similar effect, is particularly suitable for use in the present invention.
  • the acid is benzoic acid.
  • the pharmaceutical formulation has an acidic pH.
  • nicotine can be readily absorbed into the lungs.
  • the formulation has a pH of from 4.5 to 6.5.
  • the formulation has a pH of from 4.5 to 5.9.
  • the formulation has a pH of from 5.0 to 5.8.
  • the pH of the formulation is typically adjusted as required using an excess of the acid used to form the nicotine salt.
  • a poorly soluble acid is used to form the salt, another, water-soluble acid may be used to adjust the pH.
  • the formulation does not include a separate buffering agent or pH regulating agent.
  • the formulation comprises at least 75% of water. In an embodiment, the formulation comprises at least 11% of water. As noted above, high volumes of water can facilitate aerosol production and lead to improved PK characteristics. The formulation also leads to little or no observable vapour "cloud" being produced when the product is exhaled, lessening the impact of passive smoking on third parties.
  • the formulation is a liquid formulation.
  • the formulation is provided as a liquid formulation.
  • the liquid formulation can be provided in a cartridge, for use with an aerosolising or nebulizing device such as an e- cigarette, nebulizer or metered-dose inhaler [MDI].
  • the formulation is in the form of aerosolised droplets.
  • Mass Median Aerodynamic Diameter refers to the diameter at which 50% of the particles by mass are larger, and 50% of the particles by mass are smaller.
  • the size of the droplets determines the site of deposition of the particles in the respiratory tract.
  • the aerosolised droplets may have an MMAD of from 1 to 6 pm.
  • the aerosolised droplets may have an MMAD of from 2 to 4 pm.
  • the MMAD is within these ranges, the aerosolised droplets are small enough to avoid irritating the back of the throat, but large enough to settle in terminal bronchi and alveoli rather than simply being exhaled, facilitating deep lung delivery.
  • the high volume of water in the formulation of the invention facilitates the formation of such small droplets, and consequently delivery to the deep lung. This deep lung delivery can lead to a sense of smoking satisfaction in users.
  • the formulation comprises one or more flavouring agents.
  • the flavouring agent may be a natural flavouring agent or an artificial or simulated flavouring agent, and combinations of flavouring agents can be used.
  • suitable flavouring agents for use in nicotine-containing products are known in the art.
  • suitable flavouring agents include fruit flavours such as apple, banana, bergamot, cherry, grape, lemon, orange, pear, pineapple, raspberry and strawberry; plant flavours such as vanilla, nut flavours such as hazelnut; spice flavours such as cinnamon and clove; root flavours such as ginger and liquorice, mint flavours such as menthol, eucalyptol and pinene; and tobacco flavours.
  • the formulation comprises a tobacco, fruit or mint flavouring.
  • the flavouring agent is a water-soluble flavouring agent.
  • the flavouring agent is selected from acetic acid, 2-acetylpyridine, 3- acetylpyridine, 2-acetyl-5-methylfuran, a-angelica Lactone (5-methyl-3H-furan-2-one), 4,5- dimethyl-3-hydroxy-2,5-dihydrofuran-2-one, 2,5-dimethylpyrazine, 2,6-dimethylpyrazine, ethyl acetate, 2-ethyl-3(5 or 6)-dimethylpyrazine, ethyl-3-hydroxybutyrate, 5-ethyl-3- hydroxy-4-methyl-2(5H)-furanone, 5-ethyl-4-hydroxy-2-methyl-3(2H)-furanone, ethyl maltol, 2-ethyl-3(5)-dimethylpyrazine, 2-ethyl-3(6)-dimethylpyrazine, furaneo
  • the flavouring agent may be a flavouring oil, such as a natural flavouring essential oil.
  • oils include, but are not limited to ajwain oil, angelica root oil, anise oil, asafoetida, balsam of Peru, basil oil, bay oil (Laurus nobilis), bergamot oil, black pepper, buchu oil, cannabis flower essential oil, calamodin oil, caraway seed oil, cardamom seed oil, carrot seed oil, cedar oil, chamomile oil, cinnamon oil, citron oil, citronella oil, clary sage oil, coconut oil, clove oil, coffee oil, coriander oil, costmary oil, costus root oil, cranberry seed oil, cubeb oil, cumin seed oil, cypriol oil, curry leaf oil, dill oil, elecampane oil, eucalyptus oil, fennel seed oil, fenugreek oil, galangal oil, garlic oil, geranium
  • the formulation comprises one or more co-solubilisers.
  • suitable co-solubilisers include, but are not limited to propylene glycol, polyethylene glycol (PEG), glycerine, polyethylene glycol (PEG)/polypropylene glycol (PPG) co-polymers, polyvinylpyrrolidone, 1,2-hexanediol, 1,2-pentanediol, diethylene glycol mono-ethyl ether, dimethyl isosorbide, ethanol, n-butanol, n-pentanol; and mixtures thereof.
  • the co-solubiliser is propylene glycol, glycerine, or a mixture of propylene glycol and glycerine.
  • the formulation comprises one or more solubilisers.
  • Suitable solubilisers include, but are not limited to, polyoxyethylene (40) castor oil, poloxamer 407 TM (polyethylene glycol)-block-poly(propylene glycol)-block-poly(ethylene glycol), polyoxyl (35) castor oil, polyoxyl (40) castor oil, polyoxyl (40) castor oil in admixture with PPG-l-PEG 9 lauryl glycol ether, PEG (40) castor oil, PPG-l-PEG 9 lauryl glycol ether, polyoxyethylated 12- hydroxystearic acid, PEG 300, PEG 400, dioleic acid PEG 600 ester, heptyl glucoside, isostearic acid monoisopropanolamide, coconut fatty acid diethanolamide, coconut fatty acid glycol ester, coconut fatty acid monoethanolamide, coconut fatty acid PEG200 ester, coconut fatty acid PEG600 este
  • suitable solubilisers include, but are not limited to, polyoxyethylene (40) castor oil, poloxamer 407 TM (polyethylene glycol)-block- poly(propylene glycol)-block-poly(ethylene glycol), polyoxyl (35) castor oil, polyoxyl (40) castor oil, polyoxyl (40) castor oil in admixture with PPG-l-PEG 9 lauryl glycol ether, PEG (40) castor oil, PPG-l-PEG 9 lauryl glycol ether, polyoxyethylated 12-hydroxystearic acid, PEG 300, PEG 400, dioleic acid PEG 600 ester, heptyl glucoside, isostearic acid monoisopropanolamide, coconut fatty acid diethanolamide, coconut fatty acid glycol ester, coconut fatty acid monoethanolamide, coconut fatty acid PEG200 ester, coconut fatty acid PEG600 ester, oleic acid PEG600 ester,
  • the solubiliser is PEG (40) hydrogenated castor oil.
  • the formulation comprises one or more sweeteners.
  • suitable sweeteners include oxathiazinone sweeteners such as acesulfame and acesulfame K; dipeptide derivatives such as alitameTM, aspartame and aspartame derivatives and aspartame-like di- and tri-peptides such as neotame; sulfamates such as sodium cyclamate (sodium-N- cyclohexylsulfamate) and calcium cyclamate; sugar alcohols such as erythritol, xylitol, maltitol, mannitol, sorbitol, isomalt and tagatose; naturally occurring sweeteners such as xylose, glycyrrhizin and stevia; rare sugars such as d-psicose and d-allose; saccharin, sucralose, gluonic acid; and mixtures thereof.
  • the formulation is an inhalable formulation.
  • inhalable formulation is meant that the formulation is in the form of droplets suitable for inhalation by a subject.
  • the MMAD of the droplets may be 12 pm or less, or the MMAD of the droplets may be 10 pm or less. In an embodiment, the MMAD is between 1 to 6 pm, or between 2 and 4 pm.
  • the inhalable formulation can be obtained by aerosolising the liquid formulation previously described, for instance in a nebulizer. Further ingredients such as suspending agents, thickening agents and/or excipients can be included in the formulation. The inclusion of such additional components would be within the remit of one skilled in the art.
  • the pharmaceutical formulation comprises from 75 to 85 wt.% of water; from 0.1 to 8 wt. % of nicotine; from 0.1 to 15 wt.% of co-solubiliser; from 0.5 to 1.5 wt.% of sweetener; from 0.05 to 1.5 wt.% of flavouring; and from 1 to 5% of acid.
  • the nicotine is included at from 0.1 to 5%. In an embodiment, the acid is included at from 1 to 2%.
  • the pharmaceutical formulation comprises from 75 to 85 wt.% water; from 0.1 to 8 wt.% nicotine; from 0.1 to 15 wt.% co-solubiliser; from 0.5 to 1.5 wt.% sweetener; and from 0.05 to 1.5 wt. % of flavouring.
  • the pharmaceutical formulation comprises > 80 wt.% of water.
  • a method of delivering nicotine to a subject comprising providing an aerosolised formulation comprising 0.1-8% wt.% of nicotine and at least 65 wt.% water; and administering the aerosolised formulation via inhalation.
  • the formulation may be the formulation described in detail above.
  • the method may further comprise providing the formulation in liquid form, and nebulising or aerosolising the liquid formulation to form the aerosolised formulation.
  • the formulation may be supplied as a liquid, in a cartridge or similar, for use with a nebuliser. Accordingly, in an aspect of the invention there is provided a cartridge comprising the liquid formulation, and an e-cigarette or nebuliser device comprising the liquid formulation or a liquid-formulation-containing cartridge.
  • the liquid formulation may be nebulised via the application of oxygen, compressed air or ultrasonic power to form the aerosolised formulation.
  • the nebuliser is a mechanical nebuliser, a jet nebuliser, a mesh nebuliser such as a vibrating mesh nebuliser or an ultrasonic nebuliser such as a piezo or PZT nebuliser.
  • the nebuliser is a mesh nebuliser.
  • Viscosity was measured using a Cannon-Penske viscometer.
  • the viscometer is first cleaned with deionized water followed by pure ethanol which is allowed to drain away, before the device is dried in a current of air.
  • the viscometer is charged with the test-liquid by pouring it into the wider bored tube of the U-shaped apparatus until the large bulb reservoir is half- full.
  • the viscometer is placed in a thermostatted bath and temperature allowed to equilibrate.
  • the viscometer is carefully levelled, and the liquid drawn by pipette filler through the capillary of the narrower tube until the level reaches above a first fixed gradation mark.
  • the pipette filler is carefully removed, and the liquid level allowed to fall to the first fixed gradation mark, at which point a stopwatch is activated. The time taken for the level to fall to a second, lower graduated mark is recorded. The procedure is repeated four additional times and the average time calculated.
  • kinematic viscosity v, measured in mm 2 /s, is calculated by multiplying the average time by the viscosity constant - which is supplied with each individual viscometer.
  • a formulation comprising 0.3 % (w/w) of nicotine was prepared as set out below. All non- nicotine ingredients used were of food-grade quality.
  • a stock solution of 5% w/w sucralose was prepared by adding 5.0g of sucralose to 95. Og of water. The mixture was stirred vigorously until a clear solution remained.
  • a flavour complex consisting of a mixture of 0.025 g of 5-ethyl-3-hydroxy-4-methyl-2(5H) furanone and 0.05 g of cis 3-hexen-l-ol was dissolved in propylene glycol sufficient to give 5 g of solution.
  • 0.025 g of L-menthol was added to 1.0 g of KolliphorTM RH-40 and the mixture was stirred until clear. This was added to the flavour complex along with 2.50 g of the 5% sucralose solution.
  • composition of the formulations is shown in Table 1 below:
  • a formulation was prepared according to the same methodology as Example 1, comprising the following:
  • the formulation had a pH of 5.
  • the viscosity of the formulation was then measured as follows:
  • the formulation was found to have a kinematic viscosity of 1.866 m 2 /s x 10 6 cS. Its relative density was 1.048g/ml. Its dynamic viscosity was therefore 1.956 cP.
  • Nicotine formulations comprising 1.2, 1.8 and 2.4% of nicotine were prepared as outlined above, with the concentrations chosen to encompass some of the doses likely to be acceptable to users.
  • Participants were familiarized with the inhaler device using a placebo formulation on the day prior to receiving active treatment.
  • the placebo formulation was identical to the active formulation described above, with the exception that the placebo formulation did not include nicotine.
  • the nicotine inhaler device used was a MicroBaseTM Pocket AirNeb Mini Portable Nebuliser [Model No. MBPN002]. This device comprises a portable compact compressor with small delivery mouthpiece that allows a user to inhale. The average nebulization rate is
  • Nicotine is delivered from each inhale, and level of nicotine is therefore dependent on an individual's depth of inhalation and number of "puffs" over the time span of 3 minutes +/- 30 secs.
  • the device was filled with the formulations described above. Participants inhaled each time in a similar way to a cigarette. All participants were instructed to inhale at the same rate of one inhalation every 20 s +/- 5 secs over approximately 3 min (i.e., approximately eight inhalations in total). This inhalation protocol should comprise a comparable inhalation to that of a CC for most users.
  • venous blood samples were collected 5 min pre-dose. Samples were then collected at 2, 4, 6, 8, 10, 15 and 20 minutes (+/- 2 mins) post-dose (i.e., from the start of inhalation) for the measurement of plasma nicotine concentration by a liquid
  • Venous plasma nicotine concentration post-inhalation of a CC is shown by ( #).
  • the CC profile shows a rapid increase in plasma nicotine levels over the first 8 minutes, reaching a plateau at about 20 minutes.
  • the nicotine formulation of the invention showed a similar profile, particularly for the formulations comprising 1.8 and 2.4 % of nicotine.
  • Tayyarah et al. determined the total carbonyls generated during vaporization for a series of commercial e-cigarette liquids.
  • the carbonyls including formaldehyde, acetaldehyde, acrolein, propionaldehyde, crotonaldehyde, methyl ethyl ketone and butyraldehyde, were typically found to be present at values between ⁇ 0.05 to ⁇ 0.09 mg per 99 puffs, indicating that although exposure is more limited than for conventional cigarettes, low levels of toxins are still present.
  • Table 3 Nicotine formulation for degradation testing The formulation had a pH of 5.5.
  • VOCs Volatile organic compounds present in the resulting formulation vapour were analysed by assaying a single 100 ml puff trapped in a suitable solid support containing 2,4-dinitrophenylhydrazine (DNPH) which was eluted and analysed by HPLC-DAD, using UV, Rl and PDA detectors.
  • DNPH 2,4-dinitrophenylhydrazine
  • HPLC-DAD Conditions were as follows:
  • Results demonstrate that there were no detectable levels of conventional e-cigarette toxins in the vapour of the formulation, irrespective of mode of delivery, suggesting that the formulation of the present invention shows a reduction in the formation of deleterious by products, at both ambient and conventional e-cigarette temperatures.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Dispersion Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Manufacture Of Tobacco Products (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)

Abstract

La présente invention concerne une formulation pharmaceutique comprenant de la nicotine. La formulation peut être mise à l'état d'aérosol à la température ambiante pour une administration par inhalation. L'invention concerne également un procédé d'administration de nicotine à un sujet par inhalation, et spécifiquement au moyen d'un nébuliseur.
EP19727687.6A 2018-06-01 2019-05-31 Formulation de nicotine et mode d'administration Active EP3684362B1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
PL19727687T PL3684362T3 (pl) 2018-06-01 2019-05-31 Preparat nikotynowy
EP21174043.6A EP3909581A1 (fr) 2018-06-01 2019-05-31 Formulation de nicotine

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18175640.4A EP3574902A1 (fr) 2018-06-01 2018-06-01 Formulation de nicotine et mode d'administration
PCT/EP2019/064212 WO2019229249A1 (fr) 2018-06-01 2019-05-31 Formulation de nicotine

Related Child Applications (2)

Application Number Title Priority Date Filing Date
EP21174043.6A Division EP3909581A1 (fr) 2018-06-01 2019-05-31 Formulation de nicotine
EP21174043.6A Division-Into EP3909581A1 (fr) 2018-06-01 2019-05-31 Formulation de nicotine

Publications (2)

Publication Number Publication Date
EP3684362A1 true EP3684362A1 (fr) 2020-07-29
EP3684362B1 EP3684362B1 (fr) 2021-06-23

Family

ID=62528283

Family Applications (3)

Application Number Title Priority Date Filing Date
EP18175640.4A Withdrawn EP3574902A1 (fr) 2018-06-01 2018-06-01 Formulation de nicotine et mode d'administration
EP21174043.6A Pending EP3909581A1 (fr) 2018-06-01 2019-05-31 Formulation de nicotine
EP19727687.6A Active EP3684362B1 (fr) 2018-06-01 2019-05-31 Formulation de nicotine et mode d'administration

Family Applications Before (2)

Application Number Title Priority Date Filing Date
EP18175640.4A Withdrawn EP3574902A1 (fr) 2018-06-01 2018-06-01 Formulation de nicotine et mode d'administration
EP21174043.6A Pending EP3909581A1 (fr) 2018-06-01 2019-05-31 Formulation de nicotine

Country Status (13)

Country Link
US (2) US11833145B2 (fr)
EP (3) EP3574902A1 (fr)
JP (1) JP7224375B2 (fr)
CN (1) CN112218637A (fr)
AU (2) AU2019276357B2 (fr)
BR (1) BR112020024088B1 (fr)
ES (1) ES2883799T3 (fr)
MA (2) MA50205B1 (fr)
MX (1) MX390509B (fr)
PL (1) PL3684362T3 (fr)
SG (1) SG11202011761XA (fr)
WO (1) WO2019229249A1 (fr)
ZA (1) ZA202007717B (fr)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3574902A1 (fr) * 2018-06-01 2019-12-04 Yatzz Limited Formulation de nicotine et mode d'administration
GB201817865D0 (en) * 2018-11-01 2018-12-19 Nicoventures Trading Ltd Aerosolisable formulation
GB201817868D0 (en) * 2018-11-01 2018-12-19 Nicoventures Trading Ltd Aerosolised formulation
GB201817867D0 (en) * 2018-11-01 2018-12-19 Nicoventures Trading Ltd Aerosolisable formulation
GB201817859D0 (en) * 2018-11-01 2018-12-19 Nicoventures Trading Ltd Aerosolisable formulation
GB201817863D0 (en) * 2018-11-01 2018-12-19 Nicoventures Trading Ltd Aerosolisable formulation
GB201817860D0 (en) 2018-11-01 2018-12-19 Nicoventures Trading Ltd Aerosolised formulation
BR112021010222A2 (pt) * 2018-12-31 2021-08-24 Philip Morris Products S.A. Formulação de nicotina líquida compreendendo solventes imiscíveis em água
PL3905908T3 (pl) 2019-06-20 2025-03-24 Shaheen Innovations Holding Limited Ultradźwiękowe urządzenie rozpylające do użytku osobistego
FR3102041B1 (fr) * 2019-10-22 2025-02-14 Aroma Sens Edulcorant pour liquides de cigarette électronique
US12233207B2 (en) 2019-12-15 2025-02-25 Shaheen Innovations Holding Limited Mist inhaler devices
US11730193B2 (en) 2019-12-15 2023-08-22 Shaheen Innovations Holding Limited Hookah device
ES3014051T3 (en) 2019-12-15 2025-04-16 Shaheen Innovations Holding Ltd Mist inhaler devices
US11666713B2 (en) 2019-12-15 2023-06-06 Shaheen Innovations Holding Limited Mist inhaler devices
JP7583061B2 (ja) 2019-12-15 2024-11-13 シャヒーン イノベーションズ ホールディング リミテッド 超音波ミスト吸入器
US12213516B2 (en) 2019-12-15 2025-02-04 Shaheen Innovations Holding Limited Ultrasonic mist inhaler
US12121056B2 (en) 2019-12-15 2024-10-22 Shaheen Innovations Holding Limited Hookah device
PL4292632T3 (pl) 2019-12-15 2025-11-24 Shaheen Innovations Holding Limited Ultradźwiękowy inhalator mgiełki
US11589610B2 (en) 2019-12-15 2023-02-28 Shaheen Innovations Holding Limited Nicotine delivery device having a mist generator device and a driver device
US11911559B2 (en) 2019-12-15 2024-02-27 Shaheen Innovations Holding Limited Ultrasonic mist inhaler
US11944120B2 (en) 2019-12-15 2024-04-02 Shaheen Innovations Holding Limited Ultrasonic mist inhaler with capillary retainer
US12201144B2 (en) 2019-12-15 2025-01-21 Shaheen Innovations Holding Limited Hookah device
US11730191B2 (en) 2019-12-15 2023-08-22 Shaheen Innovations Holding Limited Hookah device
US12538944B2 (en) 2019-12-15 2026-02-03 Shaheen Innovations Holding Limited Nicotine delivery device with identification arrangement
BR112022011449A2 (pt) * 2019-12-18 2022-08-30 Philip Morris Products Sa Formulação para uso em um sistema gerador de aerossol
JP7609561B2 (ja) * 2020-02-05 2025-01-07 日本たばこ産業株式会社 液体加熱式の加熱型香味吸引器用の液体組成物
IL296737A (en) 2020-03-27 2022-11-01 Mcneil Ab A cartridge with nicotine
MA57567B1 (fr) * 2020-04-06 2022-09-30 Shaheen Innovations Holding Ltd Dispositifs d'inhalateur de brouillard
CN111802686A (zh) * 2020-07-27 2020-10-23 湖北中烟工业有限责任公司 含脂肪酸、植物油的雾化剂以及加热不燃烧卷烟
CN111855866A (zh) * 2020-08-25 2020-10-30 甘肃烟草工业有限责任公司 一种快速测定烟用添加剂中甲醛的方法
IL303786B2 (en) * 2020-12-15 2024-07-01 Shaheen Innovations Holding Ltd Mist inhaler devices
CN114947174A (zh) * 2021-02-25 2022-08-30 深圳市合元科技有限公司 气溶胶形成基质以及气溶胶生成系统
CN113197330A (zh) * 2021-04-28 2021-08-03 深圳市博睿生物科技有限公司 一种电子烟新型甜味剂及制备方法及应用
IL283002A (en) * 2021-05-06 2022-12-01 Nicogen Ltd Nicotine formulations and aerosols
CN113912585B (zh) * 2021-11-09 2023-02-24 深圳萨特瓦生物科技有限公司 复合尼古丁盐及其制备方法与应用、电子烟油及电子烟
US20230188901A1 (en) 2021-12-15 2023-06-15 Shaheen Innovations Holding Limited Apparatus for transmitting ultrasonic waves
CN116326810B (zh) * 2021-12-22 2026-03-17 深圳市富淼生物科技有限公司 水基雾化剂、指定用途水基雾化物、雾化弹以及雾化装置
CN114886145A (zh) * 2022-06-10 2022-08-12 广州市维城生物科技有限公司 一种水基烟碱电子烟雾化液及其制备方法
KR20240012197A (ko) * 2022-07-20 2024-01-29 주식회사 케이티앤지 표면파 아토마이저에 사용하기 위한 액상형 흡입제형, 이를 포함하는 카트리지 및 에어로졸 생성장치
KR102872477B1 (ko) * 2022-08-10 2025-10-20 주식회사 케이티앤지 니코틴 흡입성 조성물 및 이를 포함하는 에어로졸 발생 장치 및 시스템
CN116019250B (zh) * 2022-12-22 2025-02-14 东莞市吉纯生物技术有限公司 基于酸性电解水的雾化液、制备方法和酸性电解水制备方法
WO2024138377A1 (fr) * 2022-12-27 2024-07-04 思摩尔国际控股有限公司 Liquide d'atomisation, atomiseur et dispositif d'atomisation électronique
WO2024161313A1 (fr) * 2023-01-31 2024-08-08 Rai Strategic Holdings, Inc. Formulations de précurseur d'aérosol stabilisées
CN118787123A (zh) * 2023-04-14 2024-10-18 思摩尔国际控股有限公司 一种水基电子烟雾化制剂及其制备方法和应用
PL446676A1 (pl) * 2023-11-08 2025-05-12 Dmitrii Shesternenko Kompozycja liquidu do e-papierosa oraz e-papieros zawierający taką kompozycję
FR3159394A1 (fr) * 2024-02-19 2025-08-22 Swm Holdco Luxembourg Feuille de papier comprenant un extrait de plante et de la nicotine stabilisée
CN117898466B (zh) * 2024-02-29 2024-09-24 深圳市艾斯摩迪斯科技有限公司 一种复合尼古丁盐的制备方法及其应用
CN120923467A (zh) * 2025-07-31 2025-11-11 深圳曼华生物科技有限公司 尼古丁盐的制备方法、检测方法、制备的尼古丁盐及应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8301659D0 (en) * 1983-01-21 1983-02-23 Leo Ab Smoking substitutes
GB2133691B (en) * 1983-01-21 1986-05-21 Leo Ab Smoking substitutes for nasal administration
CA2231968A1 (fr) * 1998-03-11 1999-09-11 Smoke-Stop, A Partnership Consisting Of Art Slutsky Methode de production d'un medicament a base de nicotine
US7767698B2 (en) * 2002-06-03 2010-08-03 Mcneil Ab Formulation and use thereof
SE0201669D0 (sv) 2002-06-03 2002-06-03 Pharmacia Ab New formulation and use thereof
GB0712308D0 (en) * 2007-06-25 2007-08-01 Kind Group Ltd An inhalable composition
WO2014182736A1 (fr) * 2013-05-06 2014-11-13 Ploom, Inc. Formulations de sel de nicotine pour pulvérisateurs et procédés correspondants
CN110367592B (zh) * 2013-07-19 2022-12-02 奥驰亚客户服务有限责任公司 电子吸烟器具的液体气溶胶制剂
DE102015117811A1 (de) * 2015-10-20 2017-04-20 Chv Pharma Gmbh & Co. Kg Inhalator sowie wirkstoffhaltige Zubereitung für einen Inhalator
EP3574902A1 (fr) * 2018-06-01 2019-12-04 Yatzz Limited Formulation de nicotine et mode d'administration

Also Published As

Publication number Publication date
MX2020012810A (es) 2022-03-08
BR112020024088A2 (pt) 2021-02-17
US20210196700A1 (en) 2021-07-01
AU2019276357A1 (en) 2020-11-26
JP2021526147A (ja) 2021-09-30
US11833145B2 (en) 2023-12-05
EP3909581A1 (fr) 2021-11-17
ZA202007717B (en) 2026-03-25
MX390509B (es) 2025-03-11
CN112218637A (zh) 2021-01-12
EP3684362B1 (fr) 2021-06-23
MA50205A (fr) 2020-07-29
CA3099940A1 (fr) 2019-12-05
MA50205B1 (fr) 2021-09-30
AU2023202855B2 (en) 2024-08-22
PL3684362T3 (pl) 2021-12-20
BR112020024088B1 (pt) 2022-10-11
SG11202011761XA (en) 2020-12-30
US20240050424A1 (en) 2024-02-15
MA54714A (fr) 2021-11-17
AU2023202855A1 (en) 2023-05-25
ES2883799T3 (es) 2021-12-09
JP7224375B2 (ja) 2023-02-17
WO2019229249A1 (fr) 2019-12-05
AU2019276357B2 (en) 2023-04-20
NZ769793A (en) 2024-05-31
EP3574902A1 (fr) 2019-12-04

Similar Documents

Publication Publication Date Title
AU2023202855B2 (en) Nicotine formulation and mode of delivery
TWI612979B (zh) 尼古丁組成物
KR20220143077A (ko) 니코틴 및/또는 니코틴 염을 포함하는 조성물과 니코틴 및/또는 니코틴 염을 포함하는 조성물의 초음파 에어로졸화
ES2984536T3 (es) Formulación aerosolizable
NZ582152A (en) An inhalable composition comprising nicotine and oxygen
UA127838C2 (uk) Склад, здатний до утворення аерозолю
UA129123C2 (uk) Рідкий склад на основі нікотину, що містить частково водорозчинний розчинник
JP7618546B2 (ja) エアロゾル化可能な配合物
UA127723C2 (uk) Склад, здатний до утворення аерозолю
WO2023008063A1 (fr) Liquide pour cigarettes électroniques, procédé de fabrication de liquide pour cigarettes électroniques, cartouche pour cigarette électronique et cigarette électronique
CA3099940C (fr) Formulation de nicotine
HK40061470A (en) Nicotine formulation
HK40025199A (en) Nicotine formulation
HK40025199B (en) Nicotine formulation
JP7755751B2 (ja) エアロゾル化可能な材料
CN115191639A (zh) 气溶胶形成基质以及气溶胶生成系统
US20250152572A1 (en) Nicotine formulation
RU2788010C2 (ru) Способная образовывать аэрозоль композиция
RU2800011C2 (ru) Способная образовывать аэрозоль композиция
RU2806059C2 (ru) Способная образовывать аэрозоль композиция
Naji Vape as Another Drug Delivery System
WO2025072528A1 (fr) Complexes de nicotine et procédés d'utilisation dans le réglage de l'âpreté et de la cinétique de libération de la nicotine

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: UNKNOWN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20200421

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20200812

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/465 20060101AFI20201012BHEP

Ipc: A24B 15/167 20200101ALI20201012BHEP

INTG Intention to grant announced

Effective date: 20201117

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40025199

Country of ref document: HK

GRAJ Information related to disapproval of communication of intention to grant by the applicant or resumption of examination proceedings by the epo deleted

Free format text: ORIGINAL CODE: EPIDOSDIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

INTC Intention to grant announced (deleted)
GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20210414

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: TN

Ref legal event code: VAGR

Ref document number: TN/P/2021/000171

Country of ref document: TN

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602019005606

Country of ref document: DE

Ref country code: AT

Ref legal event code: REF

Ref document number: 1403695

Country of ref document: AT

Kind code of ref document: T

Effective date: 20210715

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: RO

Ref legal event code: EPE

REG Reference to a national code

Ref country code: NL

Ref legal event code: FP

REG Reference to a national code

Ref country code: SE

Ref legal event code: TRGR

REG Reference to a national code

Ref country code: MA

Ref legal event code: VAGR

Ref document number: 50205

Country of ref document: MA

Kind code of ref document: B1

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG9D

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210923

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210623

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210623

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210623

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 1403695

Country of ref document: AT

Kind code of ref document: T

Effective date: 20210623

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210924

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210623

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210923

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210623

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2883799

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20211209

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210623

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210623

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20211025

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210623

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210623

VS25 Lapsed in a validation state [announced via postgrant information from nat. office to epo]

Ref country code: MD

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210623

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602019005606

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210623

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20220324

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210623

VSFP Annual fee paid to validation state [announced via postgrant information from national office to epo]

Ref country code: TN

Payment date: 20210531

Year of fee payment: 4

REG Reference to a national code

Ref country code: BE

Ref legal event code: MM

Effective date: 20220531

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20220531

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230417

P02 Opt-out of the competence of the unified patent court (upc) changed

Effective date: 20230522

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210623

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210623

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date: 20190531

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210623

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 20250522

Year of fee payment: 7

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: MC

Payment date: 20250509

Year of fee payment: 7

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20250603

Year of fee payment: 7

Ref country code: PL

Payment date: 20250512

Year of fee payment: 7

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20250509

Year of fee payment: 7

Ref country code: ES

Payment date: 20250603

Year of fee payment: 7

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: LU

Payment date: 20250521

Year of fee payment: 7

Ref country code: IT

Payment date: 20250520

Year of fee payment: 7

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20250509

Year of fee payment: 7

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 20250601

Year of fee payment: 7

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: RO

Payment date: 20250520

Year of fee payment: 7

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CZ

Payment date: 20250512

Year of fee payment: 7

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IE

Payment date: 20250509

Year of fee payment: 7

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SE

Payment date: 20250509

Year of fee payment: 7

VSFP Annual fee paid to validation state [announced via postgrant information from national office to epo]

Ref country code: MA

Payment date: 20230504

Year of fee payment: 5

VSFP Annual fee paid to validation state [announced via postgrant information from national office to epo]

Ref country code: MA

Payment date: 20240509

Year of fee payment: 6

Ref country code: MA

Payment date: 20220520

Year of fee payment: 4

VSFP Annual fee paid to validation state [announced via postgrant information from national office to epo]

Ref country code: MA

Payment date: 20250522

Year of fee payment: 7

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210623